DeepMed Research

UNIVERSITY COLLEGE LONDON

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Private

Established: 1826-02-11

Employees: 10K

Market Cap: -

Website: http://www.ucl.ac.uk

Clinical Trials

Radiotherapy and Androgen Deprivation In Combination After Local Surgery (RADICALS) Translational Study

Not yet recruiting

Conditions: Prostate Cancer

Interventions: Drug: Luteinising Hormone-Releasing Factor Analogue

First Posted Date: 2023-11-24

Last Posted Date: 2023-11-24

Lead Sponsor: University College, London

Target Recruit Count: 2585

Registration Number: NCT06145958

Mood Awareness Psychotherapy Support

Not Applicable

Completed

Conditions: Depression, Anxiety

Interventions: Behavioral: Internet Based Psychodynamic Psychotherapy

First Posted Date: 2023-11-15

Last Posted Date: 2024-10-29

Lead Sponsor: University College, London

Target Recruit Count: 45

Registration Number: NCT06133582

Locations: 🇬🇧
University College London, London, United Kingdom

MRE Predictors of Disease Relapse After Stopping Biologics

Recruiting

Conditions: Crohn's Disease

Interventions: Diagnostic Test: MR Enterography (MRE)

First Posted Date: 2023-11-09

Last Posted Date: 2024-05-13

Lead Sponsor: University College, London

Target Recruit Count: 150

Registration Number: NCT06124287

Locations: 🇬🇧
University College London Hospital, London, United Kingdom

Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications

Phase 2

Not yet recruiting

Conditions: Paraganglioma/ Phaeochromocytoma
Medullary Thyroid Carcinoma
Bronchial and Thymic Neuroendocrine Tumour
Those Requiring Repeat Peptide Receptor Radionuclide Therapy

Interventions: Drug: Lu-177 DOTATATE (Lutathera®)

First Posted Date: 2023-11-07

Last Posted Date: 2023-12-07

Lead Sponsor: University College, London

Target Recruit Count: 110

Registration Number: NCT06121271

Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB

Phase 2

Recruiting

Conditions: Pulmonary Tuberculosis

Interventions: Drug: GSK3036656
Drug: BTZ-043
Drug: Bedaquiline (B)
Drug: Rifampicin (R)
Drug: Delamanid (D)
Drug: Isoniazid (H)
Drug: Pretomanid (Pa)
Drug: Linezolid (L)
Drug: Moxifloxacin (M)
Drug: Pyrazinamide (Z)
Drug: Ethambutol (E)

First Posted Date: 2023-11-02

Last Posted Date: 2024-10-16

Lead Sponsor: University College, London

Target Recruit Count: 2500

Registration Number: NCT06114628

Locations: 🇿🇦
TASK Eden, George, South Africa
🇹🇿
NIMR Mbeya, Mbeya, Tanzania
🇿🇦
TASK Brooklyn, Cape Town, South Africa

and more 5 locations

Hereditary Sensory Neuropathy Serine Trial

Phase 2

Recruiting

Conditions: Hereditary Sensory Neuropathy Type I

Interventions: Drug: Placebo
Drug: L-serine

First Posted Date: 2023-11-02

Last Posted Date: 2023-11-02

Lead Sponsor: University College, London

Target Recruit Count: 50

Registration Number: NCT06113055

Locations: 🇬🇧
University College London, London, United Kingdom

ADIE-FS - Aligning Dimensions of Interoceptive Experience in Patients With Functional Seizures

Not Applicable

Recruiting

Conditions: Dissociative Seizures
Non Epileptic Seizure
Functional Neurological Disorder
Psychogenic Nonepileptic Seizures
Psychogenic Pseudoseizure

Interventions: Behavioral: Interoceptive training

First Posted Date: 2023-10-30

Last Posted Date: 2024-03-04

Lead Sponsor: University College, London

Target Recruit Count: 20

Registration Number: NCT06105996

Locations: 🇬🇧
Queen Square Institute of Neurology, London, United Kingdom

Quantitative Perfusion Imaging Using Contrast Enhanced Perfusion Ultrasound, MRI and Perfusion Angiography

Recruiting

Conditions: Vascular Diseases

First Posted Date: 2023-10-27

Last Posted Date: 2024-04-24

Lead Sponsor: University College, London

Target Recruit Count: 36

Registration Number: NCT06103708

Locations: 🇬🇧
University College London Hospital, London, United Kingdom

Metabolic Responses to Exercise and Recovery

Not Applicable

Recruiting

Conditions: Metabolism
Exercise

Interventions: Device: Cornell treadmill exercise protocol

First Posted Date: 2023-10-18

Last Posted Date: 2023-10-18

Lead Sponsor: University College, London

Target Recruit Count: 48

Registration Number: NCT06088108

Locations: 🇬🇧
University of East London SportsDock, London, United Kingdom

A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma

Phase 2

Recruiting

Conditions: Large B-cell Lymphoma

Interventions: Drug: Glofitamab
Drug: Polatuzumab vedotin
Drug: Obinutuzumab

First Posted Date: 2023-10-10

Last Posted Date: 2024-12-24

Lead Sponsor: University College, London

Target Recruit Count: 99

Registration Number: NCT06071871

Locations: 🇬🇧
Kings College Hospital NHS Foundation Trust, London, United Kingdom
🇬🇧
University College London Hospitals NHS Foundation Trust, London, United Kingdom
🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy